Position in TLRY
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$0
-$135 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Derivatives in TLRY
reported options exposure · as of Mar 31, 2026CallValue
$375,907
CallShares
58,100
PutValue
$363,614
PutShares
56,200
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Walleye Capital LLC holds $49,633,459 across 26 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ANIP |
Ani Pharmaceuticals Inc
|
183,075 | $14,078,467 | |
| 2 | HIMS |
Hims & Hers Health, Inc.
|
325,753 | $6,762,632 | |
| 3 | BHC |
Bausch Health Companies Inc.
|
1,177,370 | $6,357,798 | |
| 4 | TAK |
Takeda Pharmaceutical Co Ltd
|
260,817 | $4,830,330 | |
| 5 | BIOA |
BioAge Labs, Inc.
|
151,674 | $2,652,778 | |
| 6 | ZTS |
Zoetis Inc.
|
21,328 | $2,521,182 | |
| 7 | AQST |
Aquestive Therapeutics, Inc.
|
584,977 | $2,427,654 | |
| 8 | ETON |
Eton Pharmaceuticals, Inc.
|
81,963 | $2,022,846 |
All Filings in TLRY
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $375,907 | 58,100 | Call | Sole | 2026-05-13 | |
| 2026-03-31 | $363,614 | 56,200 | Put | Sole | 2026-05-13 | |
| 2025-12-31 | $135 | 15 | Shares | Sole | 2026-02-13 | |
| 2025-12-31 | $32,508 | 3,600 | Put | Sole | 2026-02-13 | |
| 2025-12-31 | $945,441 | 104,700 | Call | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||